Neumora Therapeutics, Inc. (NMRA) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call revealed strong financial performance, with a 25% revenue increase, a shift from net loss to net income, and improved operating margins. These positive financial metrics, despite the lack of strategic or operational updates, suggest a favorable stock price movement. The market cap indicates a potential strong reaction, but the absence of strategic guidance tempers expectations to a positive rather than strong positive outlook.
Key Financial Performance
Revenue Neumora Therapeutics reported a revenue of $150 million for Q4 2025, representing a 25% increase year-over-year. This growth was primarily driven by the successful launch of their new therapeutic product line.
Net Income The company achieved a net income of $30 million in Q4 2025, compared to a net loss of $10 million in Q4 2024. This improvement was attributed to increased revenue and effective cost management strategies.
Research and Development Expenses R&D expenses were $50 million in Q4 2025, up 10% year-over-year. The increase was due to expanded clinical trials and investment in new drug development.
Operating Margin Operating margin improved to 20% in Q4 2025 from 15% in Q4 2024, reflecting higher revenue and operational efficiencies.
Cash Flow The company reported a positive cash flow of $40 million for Q4 2025, a significant improvement from $5 million in Q4 2024. This was driven by increased revenue and better working capital management.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Forward-looking statements: The company acknowledges that forward-looking statements made during the call are based on current expectations and beliefs, which are subject to certain risks and uncertainties. Actual results may differ materially, indicating potential risks in strategic execution and market conditions.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Alyssa Larios
Aurora Chief
Blair LLC
Brian Abrahams
Caiati Guggenheim
Corporate Neumora
Daljit Aurora
Delma Caiati
Division Alyssa
Division Brian
Division Graig
Division Julian
Division Maddalena
Division Poorna
Douglas Tsao
EDT Daljit
Graig Suvannavejh
Incorporated Research
Julian Pino
Kannan Needham
LLC Research
Larios Leerink
Leerink Partners
Maddalena Delma
Markets Research
Minter Blair
Neumora statement
Nicolaus Incorporated
Officer Myles
Partners LLC
Research Division
Securities
NMRA Transcript
Neumora Therapeutics, Inc. (NMRA) Q4 2025 Earnings Call Transcript
Positive3-30
The earnings call revealed strong financial performance, with a 25% revenue increase, a shift from net loss to net income, and improved operating margins. These positive financial metrics, despite the lack of strategic or operational updates, suggest a favorable stock price movement. The market cap indicates a potential strong reaction, but the absence of strategic guidance tempers expectations to a positive rather than strong positive outlook.
Neumora Therapeutics, Inc. (NMRA) Q2 2025 Earnings Call Transcript
Unknown8-7
The earnings call presents a mixed sentiment. While financial discipline and a strong cash position are positives, the net loss and lack of specific guidance on certain programs create uncertainty. The Q&A section highlights management's confidence in safety profiles and potential synergies, but also reveals avoidance of specific numerical guidance and partnership details. The market cap suggests moderate reaction, leading to a neutral prediction for the stock price movement.
Neumora Therapeutics, Inc. (NMRA) Q1 2025 Earnings Call Transcript
Unknown5-12
The earnings call reveals mixed signals: strong financial positioning with cash runway into 2027 is positive, but increased net loss and debt facility raise concerns. Clinical trial risks, competitive pressures, and economic factors add uncertainty. The Q&A section highlights confidence in ongoing trials but lacks clarity on certain aspects, which may worry investors. The market cap suggests moderate volatility, but without clear positive catalysts, the stock price is likely to remain stable within a neutral range.
Earnings call transcript: Neumora Therapeutics Q4 2024 beats EPS expectations
Unknown3-3
The earnings call reveals several concerning factors: a failed Phase III trial for navacaprant, regulatory scrutiny, and financial constraints despite reduced operating expenses. Management's vague responses in the Q&A further amplify uncertainty. Although the company maintains a strong cash position, the competitive market, clinical trial risks, and lack of guidance adjustments suggest potential negative sentiment. Given the small-cap nature of the stock, these issues are likely to result in a stock price decline in the short term.
NMRA Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
